Based on the comparison of expression percentage of immune checkpoints, we observed that classical molecules like PD1, CTLA4, TIM3, and LAG3 and newly reported molecules like CD161 were extremely low in these brain tumors, which might partly explain the difficulty for their clinical transformation in brain tumors (Figure 2F) (31). This evidence concerns the gene HAVCR2 and brain neoplasm.